With the average uninsured cost of TKI treatment close to or above $146,000 per year per patient with CML in the United States, reducing or ending treatment would yield billions in savings.
Patients with chronic myeloid leukemia (CML) treated with a first- or second-generation tyrosine kinase inhibitor (TKI) may have an increased risk of arterial and venous vascular events.
When compared to prednisone, cabozantinib failed to improve overall survival of heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).
Ponatinib resulted in durable responses after 4 years in heavily pretreated patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Adding ribociclib to letrozole significantly prolonged progression-free survival compared with letrozole alone in postmenopausal women.
Post-transplant maintenance TKI therapy is feasible and could be beneficial for patients with high-risk Philadelphia chromosome-positive leukemia.
Researchers sought to evaluate cardiac and vascular toxicities associated with long-term bosutinib treatment in patients with Ph-positive leukemia.
New study data indicates that patients with previously treated advanced kidney cancer may benefit more from cabozantinib than from everolimus.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC